Dyne Therapeutics (NASDAQ:DYN) Price Target Raised to $48.00

Dyne Therapeutics (NASDAQ:DYNFree Report) had its target price hoisted by HC Wainwright from $36.00 to $48.00 in a research note released on Monday, Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Dyne Therapeutics’ FY2025 earnings at ($1.41) EPS, FY2026 earnings at $0.23 EPS, FY2027 earnings at $1.40 EPS and FY2028 earnings at $2.97 EPS.

A number of other brokerages have also recently issued reports on DYN. Morgan Stanley started coverage on shares of Dyne Therapeutics in a report on Tuesday, April 30th. They issued an overweight rating and a $40.00 target price for the company. Piper Sandler raised their price objective on shares of Dyne Therapeutics from $27.00 to $29.00 and gave the stock an overweight rating in a research note on Wednesday, March 6th. Chardan Capital reissued a buy rating and set a $31.00 price objective on shares of Dyne Therapeutics in a research note on Monday, May 6th. Stifel Nicolaus raised their price objective on shares of Dyne Therapeutics from $35.00 to $41.00 and gave the stock a buy rating in a research note on Wednesday, March 6th. Finally, Oppenheimer reissued an outperform rating and set a $47.00 price objective on shares of Dyne Therapeutics in a research note on Monday, May 6th. One equities research analyst has rated the stock with a sell rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Dyne Therapeutics presently has an average rating of Moderate Buy and an average target price of $40.78.

Read Our Latest Stock Analysis on Dyne Therapeutics

Dyne Therapeutics Stock Down 3.4 %

NASDAQ DYN opened at $31.53 on Monday. Dyne Therapeutics has a 52-week low of $6.40 and a 52-week high of $35.98. The stock has a market capitalization of $2.76 billion, a P/E ratio of -7.94 and a beta of 1.00. The firm has a 50-day moving average price of $26.96 and a 200 day moving average price of $20.43.

Dyne Therapeutics (NASDAQ:DYNGet Free Report) last issued its earnings results on Thursday, May 2nd. The company reported ($0.81) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.81). On average, equities research analysts expect that Dyne Therapeutics will post -3.1 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Venture Fund Xi L.P. Atlas sold 159,542 shares of the firm’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $22.70, for a total transaction of $3,621,603.40. Following the sale, the insider now owns 6,352,562 shares in the company, valued at $144,203,157.40. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 30,426 shares of Dyne Therapeutics stock in a transaction on Monday, May 20th. The shares were sold at an average price of $32.96, for a total value of $1,002,840.96. Following the transaction, the insider now owns 149,647 shares in the company, valued at approximately $4,932,365.12. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Venture Fund Xi L.P. Atlas sold 159,542 shares of Dyne Therapeutics stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $22.70, for a total transaction of $3,621,603.40. Following the completion of the transaction, the insider now owns 6,352,562 shares in the company, valued at approximately $144,203,157.40. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,094,383 shares of company stock worth $26,724,672. 20.77% of the stock is owned by insiders.

Hedge Funds Weigh In On Dyne Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Wetzel Investment Advisors Inc. acquired a new position in shares of Dyne Therapeutics during the 1st quarter valued at $28,000. Ameritas Investment Partners Inc. increased its stake in Dyne Therapeutics by 28.0% during the 1st quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock worth $167,000 after buying an additional 1,291 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in Dyne Therapeutics by 355.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 7,099 shares of the company’s stock worth $94,000 after buying an additional 5,541 shares during the period. EntryPoint Capital LLC purchased a new stake in Dyne Therapeutics during the 1st quarter worth $214,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Dyne Therapeutics by 58.5% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,379 shares of the company’s stock worth $75,000 after buying an additional 3,092 shares during the period. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

(Get Free Report)

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

See Also

Analyst Recommendations for Dyne Therapeutics (NASDAQ:DYN)

Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.